Welcome to our dedicated page for 10x Genomics SEC filings (Ticker: TXG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
10x Genomics, Inc. filings document regulatory disclosures for a Nasdaq-listed life science technology company with Class A common stock. Form 8-K reports furnish quarterly and annual operating results, selected preliminary results and business updates related to single cell and spatial biology platforms, including instruments, consumables, software and product launches.
The filing record also includes definitive proxy materials covering board matters, executive compensation, equity awards and shareholder voting items, as well as Form 8-K disclosure for executive officer transitions and related compensation arrangements. These documents describe TXG's public-company governance, registered security, financial reporting events and material corporate updates.
10x Genomics, Inc. (TXG) reported that Chief Executive Officer and director Serge Saxonov made a bona fide gift of 4,000 shares of Class A Common Stock on August 20, 2026. After this gift, he directly holds 1,104,380 Class A shares and also reports indirect holdings in several family trusts for which he serves as trustee.
10x Genomics, Inc. director Sarah A. Teichmann reported two open-market sales of Class A Common Stock of TXG. On August 13, 2026 she sold 5,278 shares at $57.29 per share, and on August 14, 2026 she sold 2,273 shares at $57.15 per share, for total reported sales of 7,551 shares. Both transactions were effected pursuant to her Rule 10b5-1 trading plan adopted on May 14, 2026.
TXG shareholder Sarah A Polonius-Teichmann filed to sell common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ. The notice covers a proposed sale of 2,273 common shares with an approximate aggregate value of $129,901.95 as of 08/14/2026. Additional securities to be sold include restricted stock awards of 1,155 shares dated 11/21/2025 and 1,118 shares dated 02/21/2026. Over the past three months, a separate sale of 5,278 common shares for $302,376.62 on 08/13/2026 was reported.
ARK Investment Management LLC and its CEO and CIO, Catherine D. Wood, report beneficial ownership of 10,003,058 shares of 10x Genomics, Inc. Class A common stock as of June 30, 2026. This represents 8.56% of the outstanding Class A shares.
ARK holds 9,343,840 shares with sole voting power and 122,999 shares with shared voting power. It has sole dispositive power over 10,003,058 shares. Wood is deemed to share voting power over 9,466,839 shares and share dispositive power over the full 10,003,058 shares through her control of ARK.
10x Genomics, Inc. director John R. Stuelpnagel reported selling a total of 20,000 shares of Class A Common Stock on August 11, 2026. The sales consisted of 17,000 shares at a weighted average price of $57.5812 per share, executed in multiple trades between $57.50 and $58.1525, and 3,000 shares at $58.7250 per share in a separate transaction.
10x Genomics, Inc. reported Q2 2026 total revenue of $151.0M, down 13% from Q2 2025, mainly because prior-year results included large, non-recurring patent-license settlements. Underlying products and services revenue rose 3% to $149.1M, driven by consumables and services growth, while instrument revenue fell 47%.
Gross margin improved to 74%, helped by lower inventory write-downs, warranty costs and tariff refunds. The company posted a net loss of $17.9M for Q2 and $31.4M for the first half of 2026, versus a small profit a year earlier. Cash and cash equivalents were $502.5M plus $49.5M of marketable securities, with $43.1M of operating cash inflow in the first half.
10x acquired Proteintech Genomics, Inc. for $6.1M in cash, recording $3.7M of developed-technology intangibles and $2.4M of goodwill, and separately capitalized a $12.4M long-term supply agreement. Fair-value contingent consideration tied to the prior Scale Biosciences acquisition was $10.1M at June 30, 2026, with up to $30.0M potentially payable on future milestones. The company also resolved litigation with Takara, while other IP cases continue. Management states that, excluding one-time litigation-related items, it expects 2026 revenues to moderately increase and operating expenses to modestly decrease versus 2025.
10x Genomics reported second-quarter 2026 results with revenue of $151.0 million, down from $172.9 million a year earlier. Excluding $1.6 million and $27.3 million of non-recurring patent litigation settlement revenue in 2026 and 2025, respectively, revenue increased 3% over the prior-year quarter. Gross margin improved to 74% from 72%, driven by lower manufacturing costs including $2.6 million of tariff refunds and lower inventory write-downs, partly offset by reduced non-recurring license and royalty revenue.
Operating expenses were $132.1 million, up 39% from $95.0 million, primarily because the current quarter reflected a $3.4 million gain on settlement versus $40.7 million a year ago; excluding settlement impacts, operating expenses were approximately flat year over year. The company recorded an operating loss of $19.6 million and a net loss of $17.9 million, compared with operating income of $30.1 million and net income of $34.5 million in the prior-year period. Cash, cash equivalents and marketable securities totaled $552.0 million as of June 30, 2026. 10x Genomics raised its full-year 2026 revenue guidance to a range of $610 million to $630 million, representing 2% to 5% growth over 2025 excluding non-recurring settlement revenue, and highlighted the acquisition of Proteintech Genomics and new cancer diagnostics collaborations.
10x Genomics, Inc. Chief Executive Officer Serge Saxonov reported open-market sales of 30,000 shares of Class A common stock on June 22, 2026. The sales occurred in multiple trades at weighted average prices around $33–$36 per share, as detailed by price ranges in the filing.
The transactions were made under Saxonov’s pre-arranged Rule 10b5-1 trading plan, adopted on November 29, 2025. After these sales, he holds approximately 1,108,380 shares directly, plus additional indirect holdings through the Andromeda Trust, the Y/S Descendants’ Trust, and the Y/S Pot Trust.